EMA Authorised: HyQvia (human normal immunoglobulin) — Baxalta Innovations GmbH

View source ↗

Summary

EMA authorised HyQvia, a subcutaneous immunoglobulin product with recombinant human hyaluronidase, from Baxalta Innovations GmbH for immunodeficiency syndromes …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immunodeficiency Diseases
• Inflammatory Demyelinating Polyneuropathy

Drugs mentioned

• HYQVIA (immunoglobulin G (IgG) with recombinant human hyaluronidase)

Snippet

Status: Authorised. Therapeutic area: Immunologic Deficiency Syndromes;Polyradiculoneuropathy;Polyradiculoneuropathy, Chronic Inflammatory Demyelinating. MAH: Baxalta Innovations GmbH. Decision date: 03/04/2025